Quality control for normal liquid-based cytology: Rescreening, high-risk HPV targeted reviewing and/or high-risk HPV detection?

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 9 B, 2009, Pages 4051-4060

  Depuydt, Christophe E ^a   Arbyn, Marc ^b   Benoy, Ina H ^a   Vandepitte, Johan ^a   Vereecken, Annie J ^a   Bogers, Johannes J ^a,c  

^a Laboratory for Clinical Pathology   (Belgium)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Belgium; Cervical cancer screening; Flanders; Human papillomavirus (HPV); Quality assurance

Indexed keywords

ARTICLE; CYTOLOGY; FEMALE; GENETICS; HUMAN; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PREDICTIVE VALUE; PROSPECTIVE STUDY; QUALITY CONTROL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS LOAD;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTOLOGICAL TECHNIQUES; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; QUALITY CONTROL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD;

HUMAN PAPILLOMAVIRUS;

EID: 77449108697     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00379.x     Document Type: Article

References (32)

1. Van der Graaf Y, Vooijs GP, Gaillard HL. Screening errors in cervical cytology screening. Acta Cytol. 1987, 31:434-8.
2. Krieger P, Naryshkin S. Random rescreening of cytologic smears. A practical and effective component of quality assurance programs in both large and small cytology laboratories. Acta Cytol. 1994, 38:291-8.
3. Wilbur DC, Prey MU, Miller WM. The AutoPap system for primary screening in cervical cytology: comparing the results of a prospective, intended-use study with routine manual practice. Acta Cytol 1998, 42:214-20.
4. Melamed MR. Rescreening for quality control in cytology. Acta Cytol 1996, 40:12-3.
5. Medicare and CLIA programs. Amended 1988. Fed Regist 1992, 57:493-1257. United States Department of Health and Human Services HCFA
6. Rules and regulations. Fed Regist 1990, 55:9538-74. CLIA
7. Melamed MR, Flehinger BJ. Reevaluation of quality assurance in the cytology laboratory. Acta Cytol 1992, 36:461-5.
8. Hutchinson ML. Assessing the costs and benefits of alternative rescreening strategies. Acta Cytol 1996, 40:4-8.
9. Faraker CA. Partial rescreening of all negative smears: an improved method of quality assurance in laboratories undertaking cervical screening. Cytopathology. 1993, 4:47-50.
10. Herbert A, Johnson J, Patnick J. Achievable standards, benchmarks for reporting and criteria for evaluating cervical cytopathology. Cytopathology 1995, 6:301-3.
11. Report of the Working Party on the Internal Quality Control for Cervical Cytopathology Laboratories 1995, The Scottish Office, Edinburgh, The Scottish Office
12. Achievable standards, benchmarks for reporting, and criteria for evaluating cervical cytopathology 2000, NHSCSP, 2nd ed, Sheffield, NHSCSP publication no. 1
13. Arbyn M, Schenck U. Detection of false negative Pap smears by rapid reviewing: a meta-analysis. Acta Cytol 2000, 44:949-57.
14. Arbyn M, Schenck U, Ellison E. Metaanalysis of the accuracy of rapid prescreening relative to screening of Pap smears. Cancer 2003, 99:9-16.
15. Bibbo M, Hawthorne C, Zimmerman B. Does use of the AutoPap assisted primary screener improve cytologic diagnosis. Acta Cytol 1999, 43:23-6.
16. Wilbur DC, Prey MU, Miller WM. Detection of High Grade Squamous Intraepithelial Lesions and Tumors using the AutoPap System. Cancer 1999, 87:354-8.
17. Baker A, Melcher DH. Rapid cervical cytology screening. Cytopathology 1991, 2:299-301.
18. Vassilakos P, Saurel J, Rondez R. Direct-to-vial use of the AutoCyte PREP liquid-based preparation for cervical-vaginal specimens in three European laboratories. Acta Cytol 1999, 42:65-8.
19. Vassilakos P, Griffin S, Megevand E. CytoRich liquid-based cervical cytology test: Screening results in a routine cytopathology service. Acta Cytol 1998, 42:198-202.
20. Solomon D, Davey D, Kurman R. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002, 287:2114-9.
21. Depuydt CE, Vereecken AJ, Salembier GM. Thin-layer liquid-based cervical cytology and PCR for detecting and typing human papillomavirus DNA in Flemish women. Br J Cancer 2003, 88:560-6.
22. Depuydt CE, Benoy IH, Bailleul EJ. Improved endocervical sampling and HPV viral load detection by Cervex-Brush® Combi. Cytopatology 2006, 17:374-81.
23. Depuydt CE, Boulet GA, Horvath CA. Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types. J Cell Mol Med 2007, 11:881-91.
24. Tucker RA, Unger ER, Holloway BP. Real-time PCR-based fluorescent assay for quantitation of human papillomavirus types 6, 11, 16, and 18. Mol Diagn 2001, 6:39-47.
25. Moberg M, Gustavsson I, Gyllensten U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer 2004, 112:854-9.
26. Moberg M, Gustavsson I, Wilander E. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer 2005, 92:891-4.
27. Ylitalo N, Josefsson A, Melbye M. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res 2000, 60:6027-32.
28. Ylitalo N, Sorensen P, Josefsson A. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 2000, 355:2194-8.
29. Josefsson AM, Magnusson PK, Ylitalo N. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 2000, 355:2189-93.
30. Schlecht NF, Trevisan A, Duarte-Franco E. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer 2003, 103:519-24.
31. Bigras G, de Marval F. The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women. Br J Cancer 2005, 93:575-81.
32. Muñoz N, Bosch FX, de Sanjosthomamper. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-27.